Clinicopathologic characteristics of yes-associated protein 1 overexpression and its relationship to tumor biomarkers in gastric cancer

International Journal of Immunopathology and Pharmacology

Volumn 25, Issue 4, 2012, Pages 977-987

  Zhang, J ^a   Yang, Y C ^a   Zhu, Jin Shui ^a   Zhou, Z ^a   Chen, W X ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Biomarker; Clinicopathology; Gastric cancer; Yes associated protein 1

Indexed keywords

CD34 ANTIGEN; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; TRANSCRIPTION FACTOR YAP1; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN 1;

AGE; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CHRONIC GASTRITIS; DYSPLASIA; FEMALE; GENDER; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR VOLUME; ASSAY; BIOPSY; CLINICAL STUDY; CONTROLLED STUDY; STAINING; TUMOR INVASION;

EID: 84872934818     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201202500415     Document Type: Article

References (32)

1. Chan SW, Lim CJ, Chen L, Chong YF, Huang C, Song H, Hong W. The Hippo pathway in biological control and cancer development. J Cell Physiol 2011; 226:928-39.
2. Liu AM, Xu MZ, Chen J, Poon RT, Luk JM. Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opin Ther Targets 2010; 14:855-68.
3. Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21:2747-61. (Pubitemid 350070721)
4. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA. Expression of Yes-associated protein in common solid tumors. Hum Pathol 2008; 39:1582-9.
5. Guo J, Kleeff J, Zhao Y, et al. Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma. Int J Mol Med 2006; 17:761-7.
6. Lam-Himlin DM, Daniels JA, Gayyed MF, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA. The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway. Int J Gastrointest Cancer 2006; 37:103-9. (Pubitemid 351642210)
7. Muramatsu T, Imoto I, Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis 2011; 32:389-98.
8. Fernandez-L A, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S, Taylor MD, Kenney AM. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev 2009; 23:2729-41.
9. Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009; 115:4576-85.
10. Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 2010; 101:1279-85.
11. Tufail R, Jorda M, Zhao W, Reis I, Nawaz Z. Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas. Breast Cancer Res Treat 2012; 131:743-50.
12. Ehsanian R, Brown M, Lu H, et al. YAP dysregulation by phosphorylation or ΔNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene 2010; 29:6160-71.
13. Yuan M, Tomlinson V, Lara R, et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 2008; 15:1752-9.
14. Zhang H, Wu S, Xing D. YAP accelerates Aβ(25-35)-induced apoptosis through upregulation of Bax expression by interaction with p73. Apoptosis 2011; 16:808-21.
15. Tomlinson V, Gudmundsdottir K, Luong P, Leung KY, Knebel A, Basu S. JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis. Cell Death Dis 2010; 1:e29.
16. Kowalik MA, Saliba C, Pibiri M, et al. Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology 2011; 53:2086-96.
17. Zhang X, George J, Deb S, et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 2011; 30:2810-22.
18. Wang X, Su L, Ou Q. Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur J Cancer 2012; 48:1227-34.
19. Orr BA, Bai H, Odia Y, Jain D, Anders RA, Eberhart CG. Yes-associated protein 1 is widely expressed in human brain rumors and promotes glioblastoma growth. J Neuropathol Exp Neurol 2011; 70:568-77.
20. Kim JM, Kang DW, Long LZ, Huang SM, Yeo MK, Yi ES, Kim KH. Differential expression of Yes-associated protein is correlated with expression of cell cycle markers and pathologic TNM staging in non-small-cell lung carcinoma. Hum Pathol 2011; 42:315-23.
21. Kang W, Tong JH, Chan AW, et al. Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res 2011; 17:2130-9.
22. Da CL, Xin Y, Zhao J, Luo XD. Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. World J Gastroenterol 2009;15:4055-61.
23. García I, Vizoso F, Martín A, Sanz L, Abdel-Lah O, Raigoso F, García-Muñiz JL. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003; 10:234-41. (Pubitemid 40486955)
24. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008; 52:738-46. (Pubitemid 351600058)
25. Dong Q, Liu YP, Qu XJ, Hou KZ, Li LL. Expression of c-Cbl, Cbl-b, and epidermal growth factor receptor in gastric carcinoma and their clinical significance. Chin J Cancer 2010; 29:59-64.
26. Al-Moundhri MS, Al-Hadabi I, Al-Mawaly K, et al. Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer. Med Oncol 2012; 29:1739-47.
27. Zhang J, Ji JY, Yu M, et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 2009; 11:1444-50.
28. Czyzewska J, Guzińska-Ustymowicz K, Lebelt A, Zalewski B, Kemona A. Evaluation of proliferating markers Ki-67, PCNA in gastric cancers. Rocz Akad Med Bialymst 2004; 49:64-6.
29. Prakash I, Mathur RP, Kar P, Ranga S, Talib VH. Comparative evaluation of cell proliferative indices and epidermal growth factor receptor expression in gastric carcinoma. Indian J Pathol Microbiol 1997; 40:481-90. (Pubitemid 127511753)
30. Rojo F, Tabernero J, Albanell J, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006; 24:4309-16. (Pubitemid 46630789)
31. Smilek P, Dusek L, Veselý K, Rottenberg J, Kostrica R. Correlation of expression of Ki-67, EGFR, c-erbB-2, MMP-9, p53, bcl-2, CD34 and cell cycle analysis with survival in head and neck squamous cell cancer. J Exp Clin Cancer Res 2006; 25:549-55. (Pubitemid 46166770)
32. Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X, Zhang J, Liu T. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 2008; 8:363.